Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-101 plus stereotactic radiotherapy in limited metastatic pancreatic cancer
2020-003945-13Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IMM-101 in pancreatic cancer (PC), sponsored by Erasmus MC. Primary endpoint: Safety run-in. Started Dec 2020; status: active.
02
Drugs
IMM-101
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2020-003945-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003945-13.